Please contact us for more information or to learn if you are eligible to participate.
The primary objective of this study is to determine whether atezolizumab combined with FOLFOX and its continuation as monotherapy can significantly improve DFS compared to FOLFOX alone in patients with stage III colon cancers and dMMR.
Shravan Kumar Narmala, MD
National Cancer Institute (NCI)
Type of Trial